DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome

• Published in: Disease markers Vol. 2017; no. 2017; pp. 1 - 14
• Main Authors: Lazzaretti, Gabrielle, Reckziegel, Laura, Alves, Jayse, Dexheimer, Geórgia Muccillo, Abujamra, Ana Lucia
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2017; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Acute myeloid leukemia; Biological markers; Biomarkers; Cancer; Care and treatment; CpG islands; Deoxyribonucleic acid; Diagnosis; DNA; DNA methylation; Gene expression; Genetic transformation; Hematology; Leukemia; Leukemogenesis; Medical treatment; Methylation; Myelodysplastic syndrome; Myelodysplastic syndromes; Myeloid leukemia; Prognosis; Review; Therapeutic applications; Toxicity; Tumorigenesis
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2017/5472893

During the onset and progression of hematological malignancies, many changes occur in cellular epigenome, such as hypo- or hypermethylation of CpG islands in promoter regions. DNA methylation is an epigenetic modification that regulates gene expression and is a key event for tumorigenesis. The continuous search for biomarkers that signal early disease, indicate prognosis, and act as therapeutic targets has led to studies investigating the role of DNA in cancer onset and progression. This review focuses on DNA methylation changes as potential biomarkers for diagnosis, prognosis, response to treatment, and early toxicity in acute myeloid leukemia and myelodysplastic syndrome. Here, we report that distinct changes in DNA methylation may alter gene function and drive malignant cellular transformation during several stages of leukemogenesis. Most of these modifications occur at an early stage of disease and may predict myeloid/lymphoid transformation or response to therapy, which justifies its use as a biomarker for disease onset and progression. Methylation patterns, or its dynamic change during treatment, may also be used as markers for patient stratification, disease prognosis, and response to treatment. Further investigations of methylation modifications as therapeutic biomarkers, which may correlate with therapeutic response and/or predict treatment toxicity, are still warranted.